Clinical Trials Directory

Trials / Completed

CompletedNCT04198896

The Sakakibara Health Integrative Profile of Atherosclerotic-Carcinogenesis Hypothesis (SHIP-AC)

Clinical Aspects of Atherosclerotic-Carcinogenesis Hypothesis

Status
Completed
Phase
Study type
Observational
Enrollment
8,856 (actual)
Sponsor
Sakakibara Heart Institute · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

As previously reported (IJC Heart \& Vasculature 2017; 17: 11.), our epidemiological analysis showing high incidence of cancers in patients with atherosclerotic cardiovascular diseases as compared with those with non-atherosclerotic cardiovascular diseases may imply a clinical possibility of a role of atherosclerosis in cancer developments. In the present study, to address our hypothesis that cancer developments may come with a strength of atherosclerosis, we traced an incidence of cancers in a total of 8,856 patients with coronary artery diseases (CAD) for a median follow-up of 1,095 days (interquartile range, 719-1,469 days) using the Sakakibara Health Integrative Profile (SHIP) database.

Detailed description

In accordance with a presence or absence of poly-arterial diseases such as aortic and/or peripheral artery diseases as an indicator of a strength of atherosclerosis, an incidence of cancers and all-cause death in two cohorts of 8,140 patients with CAD-only and 716 with CAD with poly-arterial diseases were evaluated to track an incidence of cancers and ali-cause mortality during median follou-up periods of 3 to 4 years.

Conditions

Interventions

TypeNameDescription
OTHERincidece of cancersWith a continuous surveillance system to track all subsequent incidents of cardiovascular diseases and/or non-cardiovascular diseases via direct contact in the outpatient department, hospital records, and a mailed questionnaire at least once a year, an incidence of cancers was identified

Timeline

Start date
2009-01-01
Primary completion
2019-10-01
Completion
2019-10-01
First posted
2019-12-13
Last updated
2019-12-18

Source: ClinicalTrials.gov record NCT04198896. Inclusion in this directory is not an endorsement.